EULAR

Alpine Immune Sciences to Present ALPN-303 Data at American College of Rheumatology Convergence 2021 Annual Meeting

Retrieved on: 
월요일, 11월 8, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Securities Exchange Act of 1934, Lupus, Safety, Immunoglobulin G, Private Securities Litigation Reform Act, SLE, Glomerulonephritis, Cytokine, BAFF, Security (finance), NASDAQ, Technology, Inflammation, Exercise, COVID-19, Treatment, Serum, Research, Securities Act of 1933, Forward-looking statement, ID, Immunoglobulin A, ACR, Protein engineering, AbbVie, Twitter, American College of Rheumatology, U.S. Securities and Exchange Commission, LinkedIn, Directed evolution, Nature, Pharmacokinetics, Drug Quality and Security Act, Mouse, B-cell activating factor, Survival, Immunoglobulin M, Autoimmunity, DNA, Patient, ALPN, American College, EULAR, Adult, Vaccine, Pharmaceutical industry, ALPN-303, the Phase 1 Study, Alpine Immune Sciences, ALPN-303, THE PHASE 1 STUDY, ALPINE IMMUNE SCIENCES

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company, today announced a presentation in a Plenary session of the American College of Rheumatology (ACR) Convergence 2021 Annual Meeting.

Key Points: 
  • Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company, today announced a presentation in a Plenary session of the American College of Rheumatology (ACR) Convergence 2021 Annual Meeting.
  • A copy of the presentation will be available on the Scientific Publications page of the Alpine Website.
  • Alpine Immune Sciences is committed to leading a new wave of immune therapeutics.
  • SIP and TIP, and the Alpine logo are registered trademarks or trademarks of Alpine Immune Sciences, Inc. in various jurisdictions.

Evelo Biosciences Appoints Iain McInnes, M.B.Ch.B, Ph.D, to Board of Directors

Retrieved on: 
화요일, 9월 7, 2021

CAMBRIDGE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced the appointment of Iain McInnes, M.B.Ch.B, Ph.D., to its Board of Directors.

Key Points: 
  • CAMBRIDGE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced the appointment of Iain McInnes, M.B.Ch.B, Ph.D., to its Board of Directors.
  • We are pleased to welcome Iain, a world-renowned leader in rheumatology and clinical immunology, to our Board of Directors, said Simba Gill, Ph.D., Chief Executive Officer of Evelo.
  • Evelo Biosciences is a clinical stage biotechnology company developing orally delivered product candidates that are designed to act on the small intestinal axis, SINTAX, with systemic therapeutic effects.
  • Evelo currently has four product candidates in development: EDP1815, EDP1867, and EDP2939 for the treatment of inflammatory diseases and EDP1908 for the treatment of cancer.

Alpine Immune Sciences Provides Corporate Update and Reports Second Quarter 2021 Financial Results

Retrieved on: 
화요일, 8월 10, 2021
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Lupus, Industry, CD28, Oncology, Achievement, American Society of Clinical Oncology, AbbVie, Safety, Nature, LinkedIn, Patient, ASCO, EULAR, Exercise, ALPN, Private Securities Litigation Reform Act, U.S. Securities and Exchange Commission, Protein engineering, Private law, Technology, Security (finance), Securities Exchange Act of 1934, Cancer, Forward-looking statement, Clinical research, European Alliance, Immunology, Pembrolizumab, COVID-19, Research, Twitter, Annual general meeting, Society, Securities Act of 1933, Population, NASDAQ, Investment, Iovance Biotherapeutics, Webcast, Drug Quality and Security Act, Growth, Pharmaceutical industry, Health insurance, Vaccine

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today provided a corporate update and reported financial results for the second quarter ended June 30, 2021.

Key Points: 
  • Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today provided a corporate update and reported financial results for the second quarter ended June 30, 2021.
  • Alpine will host a conference call and live webcast to discuss the second quarter performance today, August 10, 2021 at 4:30 p.m. ET/1:30 p.m. PT.
  • Alpine Immune Sciences, Inc. is committed to leading a new wave of immune therapeutics.
  • SIP and TIP, and the Alpine logo are registered trademarks or trademarks of Alpine Immune Sciences, Inc. in various jurisdictions.